Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- DILI topics to be discussed
- “Idiosyncratic” DILI risk factors
- Agent-specific host risk factor associations
- Does underlying liver disease increase the risk of acute DILI?
- Statins can be safely taken in patients with chronic liver disease
- Safe use of statins in NAFLD
- Racial differences in DILI
- Mechanistic differences in DILI in AAs vs. Caucasians
- Alcohol as a risk factor for DILI
- Dose and “Idiosyncratic” DILI
- Risk factors: daily drug dose and DILI
- Pharmacologic properties “Rule of two”
- Drug metabolism and risk of DILI
- Genetic risk factors for DILI
- HLA and other genetic polymorphisms associated with individual DILI agents
- DILI risks associated with additional polymorphisms in HLA and other genes
- Is there a common genetic risk factor for iDILI?
- DILI outcomes
- Outcomes of DILI in patients with CLD
- Do DILI outcomes vary by race?
- Outcome of acute DILI in DILIN: cases considered chronic
- Most causes of “chronic” DILI in DILIN were similar to those not becoming chronic
- DILI outcomes in global drug-induced liver injury registries
- Regulatory science and DILI have advanced together
- Hyman Zimmerman, MD
- Validating Hy’s law in DILI registries
- “eDISH” created by John Senior MD and Ted Guo MD
- Differences between DI-ALF and other causes in USALFSG registry
- Thank you for listening
Topics Covered
- DILI risk factors
- Racial differences in DILI
- Statin use
- Drug metabolism
- Genetic risk factors for DILI
- Outcomes for DILI
- Regulatory science
- Hy’s law and eDISH
Links
Series:
- Gastroenterology and Hepatology
- Periodic Reports: Advances in Clinical Interventions and Research Platforms
Categories:
Therapeutic Areas:
Talk Citation
Lewis, J.H. (2021, January 31). Drug-induced liver injury: risk factors and drug development in DILI [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/ZNHJ8129.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. James H. Lewis has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Drug-induced liver injury: risk factors and drug development in DILI
Published on January 31, 2021
26 min
Other Talks in the Series: Periodic Reports: Advances in Clinical Interventions and Research Platforms
Transcript
Please wait while the transcript is being prepared...
0:00
This is Dr. James H. Lewis.
I'm a professor of Medicine and Director of Hepatology in the division of
Gastroenterology at Georgetown University Medical Center in Washington DC.
The topic for today's discussion is drug induced liver injury (DILI),
where we've been and where we are headed.
0:20
In the second part of the talk
we'll be discussing risk factors for drug induced liver injury,
including many of the host,
as well as pharmacologic risk factors, along with
the recent research into pharmacogenomic discovery.
0:39
In terms of risk factors for 'idiosyncratic' drug induced liver injury,
in the past we felt that older patients were at risk, women were at higher risk,
alcohol users might have been at high risk, it was unclear whether underlying liver disease would lead to an increased risk of DILI,
although Dr. Zimmerman did not feel that that was the case.
Polypharmacy leading to drug-drug interactions may have had a role as a risk factor.
Today we've turned our attention to the actual dose of the drug,
its degree of metabolism, the degree of lipophilicity,
and the pharmacogenomics associated with DILI.
1:21
As seen on this slide, these are examples of some of the drugs that were considered to
be at higher risk in older individuals,
children in general are less susceptible to drug injury (with certain exceptions),
salicylates and valproic acid are commonly seen in children as opposed to adults.
Obesity was linked to methotrexate and halothane,
although many of these associations were not evidence-based.
I've mentioned with acetaminophen,
fasting and malnutrition can lead to
the body's depletion of glutathione, and place patients at higher risk for injury.
Female gender was recognized across the board in most instances of DILI
with one exception, amoxicillin-clavulanate appears to have a slight male predominance.
Chronic alcoholism was a cause of injury,
and certain medications listed here, including acetaminophen,
where, because alcohol induces generation of
cytochrome P452E1 (which metabolizes acetaminophen),
it was thought that it could lead to higher levels of the NAPQI toxic metabolite,
even in patients who took therapeutic doses of acetaminophen.
That remains somewhat controversial,
although it was Dr. Zimmerman's opinion (and that of others who he worked with)
that it was a true phenomenon,
and he called it an instance of 'therapeutic misadventure'.
Co-infection with hepatitis B or C,
and even HIV, has been documented to increase the risk of
injury with anti-tuberculosis drugs, as well as antiretroviral drugs.